DBVT

DBVT

Last Updated:

Q3 '20

DBV Technologies

DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians and entrepreneurs who believed that food allergies could one day be treated safely and effectively. With this mission driving our commitment to the advancement of treatments in this field, we are investigating a potential new class of immunotherapy that aims to activate the immune system of patients through the skin.

Cash

$259M

Burn Rate (Qtr)

$6.75M

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Viaskin Peanut

Peanut allergy (for 4-11 yr olds)

CRL

TBD

Viaskin Peanut (EPITOPE)

Peanut allergy (for 1-3 yr olds)

Phase 3 to be initiated

H2 2020

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon